McDonald C F, Barter C E, Fraser K J, Hanan J A
Aust N Z J Med. 1984 Jun;14(3):239-43. doi: 10.1111/j.1445-5994.1984.tb03758.x.
The effects of corticosteroid administration to eight patients with severe thoracic systemic lupus erythematosus (SLE) were assessed in a prospective study over a mean period of 26 months by serial measurements of respiratory function, ESR, and a clinical score. Initial assessment of respiratory function showed severe restrictive ventilatory defects and impairment of carbon monoxide uptake not wholly attributable to the small lung volumes. ESR and clinical score showed high correlation coefficients with FEV1 in all patients, with VC and TLC in seven patients, and with TLCO in four patients, indicating that changes of respiratory function were reflecting the activity of the disease. This study shows that in patients with severe thoracic SLE it is valid to use serial measurements of respiratory function to assess the response to treatment and that pronounced and sustained improvement of respiratory function can be expected.
在一项前瞻性研究中，通过对呼吸功能、血沉（ESR）和临床评分进行连续测量，评估了皮质类固醇对8例重症胸段系统性红斑狼疮（SLE）患者的疗效，平均观察期为26个月。呼吸功能的初始评估显示存在严重的限制性通气缺陷以及一氧化碳摄取受损，这并非完全归因于肺容积减小。在所有患者中，ESR和临床评分与第一秒用力呼气容积（FEV1）的相关系数较高，在7例患者中与肺活量（VC）和肺总量（TLC）相关，在4例患者中与一氧化碳肺弥散量（TLCO）相关，这表明呼吸功能的变化反映了疾病的活动情况。本研究表明，对于重症胸段SLE患者，采用呼吸功能的连续测量来评估治疗反应是有效的，并且可以预期呼吸功能会有显著且持续的改善。
